Ta Hsung Tung

Array ( [id] => 17792122 [patent_doc_number] => 20220251213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Anti-B7-H4 Antibodies and Immunoconjugates [patent_app_type] => utility [patent_app_number] => 17/677283 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17677283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807450 [patent_doc_number] => 20220259285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => CD80 and CD86 Binding Protein Compositions and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/677795 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17677795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807451 [patent_doc_number] => 20220259286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => CD80 and CD86 Binding Protein Compositions and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/677814 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17677814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112826 [patent_doc_number] => 20240124576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => PREPARATION OF SIGLEC-15 BINDING PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/278388 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -121 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18278388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734746 [patent_doc_number] => 20220220205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => DOSING REGIMEN OF AVELUMAB FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/668125 [patent_app_country] => US [patent_app_date] => 2022-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8050 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611582 [patent_doc_number] => 20220153861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 17/590918 [patent_app_country] => US [patent_app_date] => 2022-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20402288 [patent_doc_number] => 12492257 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Anti-CTLA-4 antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/582839 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 61 [patent_no_of_words] => 36119 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 227 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987801 [patent_doc_number] => 20240059770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => OXYNTOMODULIN BINDING MOLECULES, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/259892 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563200 [patent_doc_number] => 20220127349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => ANTIBODIES WITH REDUCED IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 17/571905 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776605 [patent_doc_number] => 20220242954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => Antigen Binding Proteins that Bind PD-1 [patent_app_type] => utility [patent_app_number] => 17/554926 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19550953 [patent_doc_number] => 12134649 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => Anti-B7-H4 antibodies and immunoconjugates [patent_app_type] => utility [patent_app_number] => 17/547528 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 19 [patent_no_of_words] => 47382 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971938 [patent_doc_number] => 20240052030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => NOVEL FORMULATIONS FOR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/265055 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496518 [patent_doc_number] => 20240335536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => METHODS OF ENGINEERING IMMUNE CELLS FOR ENHANCED POTENCY AND PERSISTENCE AND USES OF ENGINEERED CELLS IN IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/255222 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 125209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595381 [patent_doc_number] => 20220144954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => ANTI-VISTA ANTIBODIES AND FRAGMENTS [patent_app_type] => utility [patent_app_number] => 17/529711 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512108 [patent_doc_number] => 20240343794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTESTINAL CANCER [patent_app_type] => utility [patent_app_number] => 18/037063 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18037063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578830 [patent_doc_number] => 20220135685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/523702 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817553 [patent_doc_number] => 20230391893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => ANTIBODY-LIKE PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/034193 [patent_app_country] => US [patent_app_date] => 2021-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786134 [patent_doc_number] => 20230374148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => BINDING MOLECULES THAT MULTIMERISE CD45 [patent_app_type] => utility [patent_app_number] => 18/248651 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336084 [patent_doc_number] => 20220002415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => Antibody Therapeutics that Bind CTLA4 [patent_app_type] => utility [patent_app_number] => 17/482138 [patent_app_country] => US [patent_app_date] => 2021-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17482138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657111 [patent_doc_number] => 20220177576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/478587 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478587 [rel_patent_id] =>[rel_patent_doc_number] =>)